AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 54 min read$ICUI

ICU Medical (ICUI) Reports Q2: Everything You Need To Know Ahead Of Earnings

ICU Medical (NASDAQ: ICUI) is set to report Q2 earnings Thursday after market close. The prior quarter revenue was $525.8 million, down 12.3% year over year, and it beat EPS estimates. For Q2, analysts expect revenue to decline about 2% year over year. The article cites an average analyst price target of $176.63 versus a $172 share price.

Original reporting
financialcontent.com
Published Aug 5, 2026, 3:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 4:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
ICU Medical (ICUI) Reports Q2: Everything You Need To Know Ahead Of Earnings — source image
Source · financialcontent.com
Decision brief

The 30-second read

$ICUINeutralLow
01

Why it matters

Traders can use the stated consensus revenue decline and the company’s recent beat history to frame scenarios, but the article does not disclose new company-specific catalysts or updated estimates.

02

Market read

The main tradable element is the scheduled earnings timing for ICUI, with sentiment supported by recent price strength and a history of exceeding expectations.

03

What to watch

The piece does not discuss margins, guidance, cash flow, or specific product/regulatory drivers that typically determine post-earnings direction.

Relevance 4/10Novelty 3/10Timing: ahead of Thursday after-hours earnings

Background

Pre-earnings checklist for ICU Medical ahead of its Thursday after-market-close earnings report, referencing last quarter’s results and current consensus expectations.

Company-level read

Ticker impact

$ICUINeutralMedium confidence
Context

ICU Medical is set to report earnings this Thursday after the close, with Q2 revenue and EPS expectations discussed ahead of the print.

Expected impact

Likely elevated volatility into the earnings release, with direction dependent on whether results beat the stated revenue decline expectation.

Evidence & confidence

The only concrete company-specific facts are last quarter’s reported revenue/EPS beat and the current quarter’s consensus revenue decline; there is no new guidance, estimate change, or event beyond the scheduled earnings timing.

Market effects

Sector

Peers’ recent results (Merit Medical, Penumbra) are used as a read-across, but the article provides no new sector data beyond those cited outcomes.

Regional

None specified.

Global

None specified.

Counterpoint

What could challenge this read

If the market is already positioned for a beat, the stock could react negatively to any modest miss versus the revenue decline expectation, even if EPS beats.

Key entities

  • company
    ICU Medical

    NASDAQ-listed medical device company reporting earnings this Thursday after the close.

  • company
    Merit Medical Systems

    Peer cited as having delivered Q2 revenue growth and a stock reaction after results.

  • company
    Penumbra

    Peer cited as having reported Q2 revenues in line with consensus.

Read at source← All news

Related articles

AUG 27
$ICUIMed

ICU Medical rating upgraded by S&P on stronger credit metrics

S&P Global Ratings upgraded ICU Medical Inc. to 'BB' from 'BB-', citing improved credit metrics and strong operating performance. The company's adjusted leverage decreased to 3.1x in Q2 2026, with free operating cash flow exceeding expectations. ICU Medical used proceeds from asset sales and cash flow to reduce debt. S&P projects mid-single-digit revenue growth and margin improvement through 2027, with a stable outlook based on expected debt and cash flow metrics.

investing.com2 min
AUG 14
$ICUIMedAI 8/10

ICU Medical (ICUI) Q2 2026 Earnings Call Transcript

ICU Medical (ICUI) reported Q2 2026 revenue of $551.7M, up 1% reported and 6% organic excluding IV Solutions divestiture and currency. Infusion Systems revenue was $189.0M (+12% organic), Consumables $289.3M (+5% organic). Adjusted EBITDA was $110.0M (+10%). Full-year guidance raised to $415M-$435M EBITDA and $8.60-$9.00 EPS.

fool.com7 min
AUG 10
$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ:ICUI) shares rose 10.2% after the company reported Q2 results that beat Wall Street and lifted full-year guidance. Adjusted EPS was $2.37 vs $1.91 expected, revenue was $551.7 million vs forecasts, and free cash flow improved to $61.64 million. Full-year adjusted EPS guidance was raised to $8.80 (midpoint).

finance.yahoo.com4 min
AUG 7
$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ: ICUI) shares rose 10.2% after the company reported Q2 adjusted EPS of $2.37, above the $1.91 consensus, and revenue of $551.7 million, above forecasts. Free cash flow improved to $61.64 million from -$8.49 million a year earlier. ICU Medical raised full-year adjusted earnings guidance to $8.80 per share (midpoint).

financialcontent.com3 min
AUG 6
$ICUIMedAI 8/10

ICU Medical (NASDAQ:ICUI) Reports Strong Q2 CY2026

ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results. Revenue rose 1.5% year over year to $551.7 million, beating Wall Street’s revenue estimate by 3.5%. Non-GAAP adjusted EPS was $2.37, up from $2.10 and 23.8% above consensus. The stock rose 1.4% to $168.02 after the release.

financialcontent.com4 min